BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Risankizumab
Related studies linked through entity extraction aliases.
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
- Status
- COMPLETED
- Phase
- PHASE2
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE2
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
- Status
- COMPLETED
- Phase
- PHASE2